Opening the book…
Hemostasis is most efficient in the smaller blood vessels, specifically arterioles and venules where the body can swiftly respond to injuries and minimize blood loss. On the other hand, when an injury occurs in an artery, it typically leads to more substantial blood loss compared to damage in a vein. This discrepancy arises due to variations in blood pressure and the distinct characteristics of arterial and venous vessels.
Under normal physiological conditions, several key mechanisms prevent the inappropriate formation of blood clots. Nitric oxide (NO), produced by endothelial cells lining the blood vessels, acts as a vasodilator that helps clear procoagulant factors and reduces the likelihood of platelet adhesion, aggregation, and fibrinogen binding. NO accomplishes this by inhibiting the TXA₂ receptor, which is involved in platelet activation. Additionally, endothelial cells, which line the innermost layer of the blood vessel walls, produce prostacyclin, a prostaglandin with vasodilatory effects. Prostacyclin disrupts platelet adhesion and aggregation by inhibiting the binding of vWF, the activation of TXA₂, and the release of platelet granules. Basophils and mast cells also contribute to clot prevention by releasing heparin, which forms a protective glycocalyx coat on the inner surface of blood vessels. This glycocalyx layer acts as a barrier that prevents platelets from adhering to the vessel walls, inhibiting the initiation of clot formation. Together, these natural mechanisms keep blood in a non-clotting state under normal circumstances, ensuring smooth blood flow and preventing the formation of harmful clots within healthy vessels.
When an injury or surgical intervention occurs, it damages blood vessels and initiates a complex, multi-step process that halts bleeding and ultimately dissolves the clot (Figure 11). This process, known as hemostasis, consists of several tightly regulated stages including vascular constriction, platelet plug formation, and coagulation (blood clotting) (Figure 12). Any malfunction or failure in these steps can lead to hemorrhage, characterized by uncontrolled bleeding. The key players in hemostasis are endothelial cells, platelets, and clotting factors.15
Figure 11 | A Typical Response to Injury | The sequential steps of hemostasis following injury or surgical intervention begins with the initial insult, leading to bleeding. This is followed by the body's natural mechanisms to arrest the bleeding and ultimately dissolve the clot after healing is complete.
Figure 12 | Summary of the Steps involved in Hemostasis | A schematic diagram illustrating the sequential steps of hemostasis after injury or surgical intervention. This process includes: (1) immediate vasoconstriction to reduce blood flow (1-2 seconds), (2) the formation of a platelet plug (primary hemostasis; 20 seconds), (3) the activation of the coagulation cascade leading to a fibrin clot (secondary hemostasis; 2-6 minutes), and (4) fibrinolysis, the breakdown of the clot.
Vascular Spasm
Vasoconstriction, a critical component of the hemostasis process, plays a pivotal role in preventing excessive blood loss following an injury or surgical intervention. When a vessel is damaged or a surgical procedure is performed, a sequence of events unfolds to initiate vasoconstriction and maintain vascular integrity. Traumatized tissues, along with sensory impulses such as pain signals, release various chemical substances into the surrounding environment. The body's neurogenic and myogenic reflexes come into play as a response to the injury or surgical trauma. These reflexes help initiate the vasoconstrictive process. Endothelial cells respond to the injury by releasing specific vasoconstrictor agents, such as endothelins. Simultaneously, there is a decrease in vasodilators and anticoagulants (such as thrombomodulin and heparin, which prevent blood clot formation). This loss further contributes to vasoconstriction. The immediate result of these coordinated actions is the initiation of a vascular spasm, which occurs remarkably quickly, typically within one to two seconds after the injury (Figure 14). The contraction of the smooth muscle lining within the vessel wall drives this spasm.
The vascular spasm response, generally lasting for about 30 minutes, is a crucial early step in hemostasis, although in some cases, it can persist for extended periods, potentially lasting hours. Overall, vasoconstriction serves as a rapid and effective mechanism to reduce blood flow to the injured area, contributing significantly to the prevention of blood loss and facilitating subsequent stages of the hemostatic process.15
Formation of the Platelet Plug
In the second stage of hemostasis, platelet plug formation, platelets, which normally circulate freely in the plasma, respond rapidly to injury. This stage involves three key steps: platelet activation, adhesion, and aggregation. Activated platelets adhere to the exposed site of injury, then clump together, forming a platelet plug that is crucial for stopping blood loss and initiating the clotting process.
Injury or surgical intervention exposes the subendothelial matrix within the blood vessel. The subendothelial matrix becomes accessible to platelets, attracting them to the site of injury. Platelets bind to the exposed collagen within the subendothelial matrix through a specialized plasma protein known as vWF. This adhesion is mediated by the glycoprotein complex GP Ib-IX-V and GP VI surface receptors. The initial platelet adhesion to collagen activates further platelets to join the growing plug, initiating a positive feedback mechanism. As platelets adhere, they become activated. This process leads to the release of contents from platelet granules, including ADP, serotonin, and thromboxane A2 (TxA2). Activation of GP IIb/IIIa allows for fibrinogen binding, facilitating platelet aggregation.The activation of PLC results in the production of IP3, which triggers the release of calcium ions, catalyzing the release of contents from dense and alpha granules. This initiates a positive feedback loop that activates additional platelets. Concurrently, DAG and PKC contribute to a rearrangement of the platelet cytoskeleton, transforming the platelets into a flat and spiky shape that enhances their ability to bind to vWF. Additionally, phospholipase A2 is activated, leading to the release of arachidonic acid, which is converted into TxA2 with the aid of cyclooxygenase-1 (COX-1). This compound further promotes platelet activation. Inflammatory agents released at the injury site cause platelets to swell and display receptors, such as GpIb and GPIIb-GpIIIa, facilitating the release of ADP and the production of TXA₂. This process uncovers fibrinogen receptors on the platelet surface, allowing fibrinogen (factor I) to link platelets together and form a platelet plug. The activation of new platelets continues to enhance this positive feedback loop, leading to the cross-linking of more platelets and reinforcing the platelet plug.
A critical event in this process is the formation of the GpIIb-GpIIIa receptor complex, which links activated platelets together (Figure 13). The linked and activated platelets clump together, resulting in platelet aggregation (Figure 14). This aggregation renders the platelets spiky and sticky, enhancing their adhesive properties. The cumulative effect of platelet aggregation is the formation of the primary platelet plug. This plug helps block the breach in the blood vessel, acting as the first line of defense against excessive bleeding. The formation of this primary platelet plug is the initial defense against blood loss, preventing excessive bleeding and setting the stage for the subsequent stages of hemostasis. Actin and myosin contraction within the platelets further stabilize the plug by enhancing its strength during the healing process. In addition, fibronectin and PDGF contribute to repairing damaged vessel walls, supporting tissue regeneration and repair.16
Figure 13 | Activation of Platelets | Illustration of platelet activation and aggregation. Following vascular injury, platelets adhere to exposed collagen in the subendothelial matrix via von Willebrand factor (vWF) and glycoprotein Ib-IX-V (GP Ib-IX-V). This triggers platelet activation, leading to the release of granules containing ADP, serotonin, and thromboxane A2 (TxA2). Activation of glycoprotein IIb/IIIa (GP IIb/IIIa) allows for fibrinogen binding, facilitating platelet aggregation and the formation of a platelet plug.
Coagulation
Coagulation, also known as blood clotting, is the foremost and most dominant hemostatic defense mechanism against blood loss. This intricate and precisely regulated process is essential for preventing excessive bleeding and plays a pivotal role in wound healing. Coagulation is characterized by a highly orchestrated sequence of events, often referred to as the coagulation cascade. This cascade is initiated upon injury and leads to the activation of a series of clotting factors. These factors act in a precise order, each triggering the next in line, much like a cascade of falling dominos. The ultimate aim of this cascade is to generate a meshwork of insoluble fibrin strands that serve as the framework for the blood clot. The culmination of the coagulation cascade is the formation of fibrin strands. Fibrin is an insoluble filamentous protein that forms a mesh-like structure at the site of injury. This fibrin mesh traps blood cells, including platelets, creating a cohesive and sturdy clot that seals the breach in the blood vessel. This process is instrumental in limiting blood loss and initiating the healing process.
One of the critical aspects of coagulation is its specificity and localization. The coagulation cascade and subsequent fibrin formation are confined to the precise location of the vessel injury. This spatial precision ensures that clot formation occurs exclusively where it is needed, preventing the formation of unwanted clots within intact blood vessels, a condition known as thrombosis. Within the coagulation cascade, a group of chemical agents, predominantly serine proteases known as clotting factors (or coagulation factors), initiate a series of reactions that, in turn, activate additional coagulation factors. While intricate, this process initiates along two pathways, the extrinsic or tissue factor pathway that is typically set in motion by traumatic injury and the intrinsic pathway which is triggered by internal damage to the vessel wall. These pathways eventually converge into a third pathway known as the common pathway, as illustrated in Figure 13. All three pathways rely on the participation of 12 well-established clotting factors, including calcium ions and vitamin K, as outlined in Table 2. The liver and platelets primarily produce these clotting factors.17
Figure 14 | Overview of hemostasis | 18 (a) Depicts the sequential stages of blood clotting: injury, vascular spasm, platelet plug formation (highlighting platelet activation and aggregation), and coagulation (showing fibrin mesh formation). (b) Illustrates the coagulation cascade, including the intrinsic, extrinsic, and common pathways, culminating in the conversion of fibrinogen to fibrin and the formation of a cross-linked fibrin clot.
Clotting Factors
Clotting factors are a group of serine proteases, which are enzymes involved in the coagulation process. These proteases play a pivotal role in the cascade of events that lead to the formation of blood clots. Several clotting factors rely on vitamin K for their proper functioning. Specifically, factors II (prothrombin), VII, IX, and X require vitamin K as a cofactor. Vitamin K ensures that these factors are appropriately activated and functional in the coagulation process. Bile salts are essential for the absorption of vitamin K from the large intestine.
Clotting factors exhibit varying half-lives in the bloodstream, reflecting differences in their stability and turnover. Typically, most clotting factors have a half-life ranging from 1.5 to 3 days, ensuring their presence in circulation for an adequate duration. Notably, factor VII has a shorter half-life of approximately 6 hours, while cofactors V and VIII have slightly longer half-lives of 8 to 12 hours.
The 12 clotting factors are assigned Roman numerals I through XIII, not necessarily in the order of their activation but according to the sequence of their discovery. Factor VI was initially considered a distinct clotting factor but is now believed to be identical to factor V. Instead of renumbering the other factors, factor VI was retained as a placeholder. Vitamin K, unlike most vitamins, is not solely obtained through dietary sources; it is also synthesized by bacteria residing in the large intestine. Calcium ions, denoted as factor IV, are acquired from dietary intake and bone resorption.19
|
Clotting Factor Number |
Clotting Factor Name |
Type of Molecule |
Location |
Source Pathway(s) |
|---|---|---|---|---|
|
I |
Fibrinogen |
Plasma protein |
Liver |
Common; Converted into fibrin |
|
II |
Prothrombin |
Plasma Protein |
Liver |
Common; Converted into thrombin |
|
III |
Tissue Thromboplastin or Tissue Factor |
Lipoprotein mixture |
Damaged cells & platelets |
Extrinsic |
|
IV |
Calcium Ions |
Inorganic ions in plasma |
Diet, platelets, bone matrix |
Entire process |
|
V |
Proaccelerin |
Plasma protein |
Liver, platelets |
Extrinsic and intrinsic |
|
VII |
Proconvertin |
Plasma protein |
Liver |
Extrinsic |
|
VIII |
Antihemolytic Factor A |
Plasma protein |
Platelets and endothelial cells |
Intrinsic; Deficiency results in Hemophilia A |
|
IX |
Antihemolytic Factor B (Plasma Thromboplastin Component) |
Plasma protein |
Liver |
Intrinsic; Deficiency results in Hemophilia B |
|
X |
Stuart–prower Factor (thrombokinase) |
Plasma protein |
Liver |
Extrinsic and intrinsic |
|
XI |
Antihemolytic Factor C (Plasma Thromboplastin Antecedent) |
Plasma protein |
Liver |
Intrinsic; Deficiency results in hemophilia C |
|
XII |
Hageman Factor |
Plasma protein |
Liver |
Intrinsic; Initiates clotting in vitro; also activates plasmin |
Extrinsic Pathway
The more rapid and direct response, the extrinsic or tissue factor pathway, is initiated when damage occurs to the surrounding tissues, often due to traumatic injury. In this pathway, extravascular cells located outside the bloodstream are exposed to blood plasma and release a substance called factor III (thromboplastin). Factor III then triggers a sequence of events involving the addition of calcium ions and factor VII (proconvertin), which is activated by factor III. These components come together to form an enzyme complex. This enzyme complex subsequently activates factor X, setting in motion the common pathway. Notably, the events in the extrinsic pathway occur rapidly, typically within seconds. The sequence of events in the extrinsic pathway can be summarized as follows:
Tissue trauma → Release of tissue thromboplastin (or tissue factor) + Factor VII + Membrane phospholipid + Calcium ions → Activation of Factor X.
Intrinsic Pathway
The intrinsic pathway is a more intricate and extended process involving numerous clotting factors that are inherent to the blood. While it can be initiated by tissue damage, such as that caused by arterial disease, it is most commonly triggered when factor XII comes into contact with foreign substances, such as when blood is placed in a glass test tube. Within the body, factor XII becomes activated when it encounters negatively charged molecules, including inorganic polymers and phosphate generated earlier in the sequence of reactions within the intrinsic pathway. Factor XII initiates a series of reactions that subsequently activate factor XI, followed by factor IX (or plasma thromboplastin). Simultaneously, chemicals released by platelets enhance the speed of these activation reactions. Ultimately, factor VIII from platelets and endothelial cells combines with factor IX (antihemolytic factor B or plasma thromboplastin) to form an enzyme complex that activates factor X, initiating the common pathway. The events within the intrinsic pathway typically conclude within a few minutes.
Common Pathway
The intrinsic and extrinsic pathways ultimately converge into a shared route, aptly named the common pathway. This pathway leads to the production of fibrin, which is crucial for sealing off the vessel. Once factor X has been activated through the intrinsic or extrinsic pathway, the enzyme prothrombinase catalyzes the conversion of factor II, an inactive enzyme known as prothrombin, into the active enzyme thrombin. Thrombin must normally exist in an inactive form in circulation; otherwise, clots would spontaneously form, which is incompatible with life. Subsequently, thrombin transforms factor I, the insoluble fibrinogen, into soluble fibrin protein strands. Factor XIII then plays a pivotal role in stabilizing the fibrin clot (Figure 13). Within the stabilized clot, contractile proteins contract, exerting force on the fibrin threads, akin to tightening shoelaces. This contraction process not only brings the clot's edges closer together but also expels a small amount of fluid called serum, which is essentially blood plasma minus its clotting factors.17
|
Clotting Factors |
Mechanisms of action |
|---|---|
|
Vitamin K |
Needed as a cofactor in the production of many clotting factors by the liver. |
|
Calcium Ion |
Needed in the formation of prothrombin activator which activates the common pathway; also acts with factor VIII during clot retraction. |
|
Prostacyclin (PGI2) |
Prevents platelet adhesion and therefore clotting cascade from taking place. |
|
Thrombin |
Activates platelets, endothelial cells, leukocytes; removes pairs of polypeptides to form the fibrin monomer. Thrombin also activates plasminogen into plasmin. |
|
Thrombomodulin |
Slows the effect of thrombin. Activates protein C when combined with thrombin. |
|
Heparin |
Increases the action of antithrombin III 100 to 1000-fold. |
|
Antithrombin III |
A serine protease inhibitor that inhibits proteases IX through XII. Its inhibitory function is greatly increased when bound to heparin. |
|
ADP |
Provides a sticky coat on the surface of the platelet helping them stick to one another. |
|
Serotonin |
Constriction of the vessel. |
|
Thromboxane A2 |
Attracts more platelets to the site of injury; vasoconstriction. |
|
Tissue Plasminogen Activator (tPA) |
Converts plasminogen to plasmin. |
|
Warfarin |
Inactivates vitamin K, causing clotting factors to not be present in the blood. |
|
Plasmin |
Digests fibrinogen, factor V, factor VIII, factor XIII, and prothrombin. |
Blood Coagulation Tests
From a clinical perspective, the time required for blood to clot is a valuable indicator of the proper functioning of platelets, clotting factors, and other components involved in the clotting process. This measurement is known as bleeding time, and in a typical scenario, it should be between 2 to 6 minutes.
Thrombin time is employed to assess fibrinogen concentration, while prothrombin time (PT) gauges the time taken to form a clot when tissue thromboplastin is present. Normally, PT falls within the range of 12 to 14 seconds. PT is frequently employed to evaluate the extrinsic and common pathways, which involve factors II, V, VII, and X, as well as vitamin K, and is used in monitoring patients on warfarin therapy (Figure 15).
Another relevant parameter is the activated partial thromboplastin time (aPTT), which measures the time needed to form a clot when plasma thromboplastin is introduced. This process typically takes about 30 seconds and tests the intrinsic and common pathways, including factors VIII, IX, and XI (Figure 15). aPTT is commonly utilized for patients undergoing heparin therapy. Factors must be reduced by more than 30 percent to see a change.
Figure 15 | Hemostasis | The coagulation cascade, showing the intrinsic pathway (Factors XII, XI, IX, VIII), extrinsic pathway (Factor VII), and the common pathway (Factors X, V, and II/Prothrombin leading to Thrombin). The associated laboratory tests, aPTT and PT, are also indicated.
The International Normalized Ratio (INR) is a calculated value standardizing PT results. It is determined by dividing the patient's prothrombin time by the normal mean prothrombin time. An INR reading falling between 0.9 and 1.3 is considered normal, while an elevated INR indicates anticoagulation therapy. Factors must be reduced by more than 30 percent to see a change.
Activated clotting time (ACT) is a laboratory test that assesses the clotting time of whole blood when diatomaceous earth is introduced to activate the intrinsic clotting pathway. It is used to monitor clotting time in response to high-dose heparin therapy. Typically, a normal ACT falls within 90 to 130 seconds. This test is commonly employed to monitor heparin therapy in the operating room. However, it is worth noting that the ACT may not be highly sensitive in detecting certain clotting abnormalities. Several factors can influence the ACT results. Conditions like hypothermia, thrombocytopenia (a low platelet count), and deficiencies in fibrinogen, factor VII, or factor XII can impact the test outcome.20
Regulation of Blood Clotting
The regulation of blood clotting is a multifaceted process that precisely controls clot formation to prevent both excessive bleeding and inappropriate thrombosis. This intricate regulation involves several key mechanisms. Anticoagulants, including inhibitors of coagulation factors, play a crucial role in limiting clot formation. Fibrinolytic agents, on the other hand, are responsible for breaking down existing clots. The body's ability to produce both these types of agents is essential for maintaining hemostasis and is also leveraged commercially to create a variety of therapeutic substances used to treat various pathological conditions.
Fibrinolysis
The clot must eventually be dismantled as the healing vessel seeks to return to its normal blood flow. This gradual breakdown of the clot is known as fibrinolysis, and it involves a rather intricate sequence of reactions that include factor XII and protein-catabolizing enzymes. During this process, the inactive plasminogen protein, synthesized in the liver, undergoes activation to become plasmin, a proteolytic enzyme. Activation of plasmin occurs through various mechanisms, including the gradual release of tPA from injured tissue, the presence of urokinase produced by the kidneys, and, in specific situations, streptokinase secreted by streptococci bacteria. Plasmin then progressively disassembles the fibrin strands within the clot into smaller fibrin degradation products. Furthermore, bradykinin, a vasodilator, is released during this phase which counteracts the vasoconstrictor effects of serotonin and prostaglandins, which were initially released by the platelets. As a result, the smooth muscle in the vessel walls relaxes, restoring normal circulation.21
Anticoagulants
An anticoagulant is a substance that counteracts the process of coagulation. Within the circulation, various plasma anticoagulants regulate and confine coagulation to the injured region, restoring the blood to its normal, clot-free state. Tissue factor pathway inhibitor (TFPI) prevents the conversion of inactive factor VII into its active form in the extrinsic pathway. Thrombomodulin, expressed on endothelial cells' surface, interacts with thrombin. This interaction leads to the activation of protein C, a plasma protein. Once activated, protein C plays a crucial role in deactivating clotting factors VIIIa and Va. Additionally, protein S acts as a cofactor for protein C, and both proteins depend on vitamin K for their activity. Antithrombin III counters factors IX - XII and opposes the transformation of prothrombin (factor II) into thrombin within the common pathway. Additionally, as previously mentioned, basophils release heparin, a polysaccharide with short-acting anticoagulant properties. Heparin acts against prothrombin as well as factors IX through XII. Notably, heparin significantly enhances the action of antithrombin III, increasing its effectiveness by 100 to 1000-fold. When used alone, heparin, a conjugated polysaccharide, exerts limited activity unless it combines with antithrombin III. This action influences both the intrinsic and common coagulation pathways, which can be evaluated using the PTT and ACT tests. However, its effect has a short half-life, and reversal can occur within about 4 hours, particularly when overdosed. To counteract an overdose, an antagonist called protamine can be administered. Heparin undergoes metabolism by heparinase, degradation by macrophages, and renal excretion. Importantly, it does not cross the placenta, making it safe for use during childbirth. A pharmaceutical form of heparin is often administered as a therapeutic measure, particularly in surgical patients at risk of blood clots.
Low molecular weight heparins, commercially prepared, function by inhibiting factor X and have a longer half-life than heparin. They do not significantly affect the aPTT assay but are incompletely reversible with protamine. In situations requiring swift reversal, fresh frozen plasma can be employed.
Cryoprecipitate is obtained through the controlled thawing of fresh frozen plasma (FFP), leading to the precipitation of larger molecules. It primarily consists of fibrinogen and factor VIII, along with smaller quantities of factor XIII, vWF, and fibronectin. Cryoprecipitate is employed to replenish fibrinogen levels in patients experiencing acquired hypofibrinogenemia and associated bleeding, typically occurring in situations such as surgical bleeding or trauma.
Warfarin functions by inhibiting Vitamin K and impacts the extrinsic and common pathways of coagulation. It has a relatively long half-life of approximately 35 hours, necessitating several days for its effects to be reversed, partly because it binds to proteins in the blood. The impact of warfarin can be assessed through tests like the PT and the INR. Quick reversal of its anticoagulant effects can be achieved using fresh frozen plasma, which contains all procoagulants except platelets, along with Vitamin K supplementation.
Aspirin or acetylsalicylic acid possesses multiple biochemical activities, one of which is its anticoagulant effect. It effectively inhibits platelet aggregation. Aspirin acetylates cyclooxygenase, rendering it non-functional for an extended period (typically 4 to 7 days). This permanent inhibition prevents the conversion of arachidonic acid into TXA₂, thereby inhibiting platelet aggregation. In contrast, other NSAIDs like ibuprofen offer only temporary effects, lasting 24 to 48 hours. Plavix, on the other hand, is an anti-ADP agent that provides a permanent effect in inhibiting platelet function.
Fibrinolytic (thrombolytic) agents constitute a class of drugs that accelerate the degradation of abnormal clots. Administering a thrombolytic agent to a patient within three hours following a thrombotic stroke significantly improves their prognosis. However, it is crucial to distinguish between strokes caused by thrombi and those resulting from hemorrhage before commencing treatment. tPA is an enzyme that catalyzes the conversion of plasminogen into plasmin, the primary enzyme responsible for clot breakdown. While it is naturally released by endothelial cells, it is also utilized in clinical medicine. Urokinase and streptokinase are two other fibrinolytic agents that activate plasminogen, thereby enhancing the breakdown of fibrin.22
This page titled 8.11: Hemostasis was last modified on Thu, 20 Mar 2025 00:05:33 GMT and is shared under a CC BY-NC-SA 4.0 license and was authored, remixed, and/or curated by Chaya Gopalan (Consortium of Academic and Research Libraries in Illinois (CARLI)) .
The book could not be loaded just now.